Outlook Therapeutics (NASDAQ:OTLK) Announces Quarterly Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) released its quarterly earnings results on Friday. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Price Performance

Shares of Outlook Therapeutics stock traded up $0.08 during trading hours on Friday, hitting $1.78. The company had a trading volume of 413,239 shares, compared to its average volume of 694,927. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85. The company has a market cap of $42.04 million, a P/E ratio of -0.17 and a beta of 0.47. The company’s 50-day moving average is $3.88 and its two-hundred day moving average is $5.94.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on OTLK. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. BTIG Research dropped their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday, November 29th. Finally, Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.34.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.